| Autor: |
Tilly W. Hulscher, John M. van Baal, Ronney A. De Abreu, Marinka A.H. Bakker, Jos P.M. Bökkerink |
| Rok vydání: |
1987 |
| Předmět: |
|
| Zdroj: |
The Role of Pharmacology in Pediatric Oncology ISBN: 9789401083959 |
| DOI: |
10.1007/978-94-009-4267-7_14 |
| Popis: |
Methotrexate (MTX) and 6-mercaptopurine (6-MP) are widely used in the maintenance treatment of acute lymphoblastic leukemia (ALL) in children. Based on their biochemical interactions there are reasons to support a combination therapy of both drugs. MTX binds tightly to dihydrofolate reductase, the enzyme that catalyses the reduction of dihydrofolate to tetrahydrofolate. Tetrahydrofolate coenzymes are required for one-carbon transfer reactions in purine de novo synthesis and thymidylate biosynthesis (Figure 1). As a consequence a purine-less and a thymidylate-less state will occur, ultimately resulting in inhibition of DNA biosynthesis [1–10]. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
